INDOCO REMEDIES LTD. - 532612 - Announcement Under Reg 30 Of SEBI LODR -Issuance Of Corporate Guarantee
The Board of Directors at its meeting held on 19th October, 2023 has interalia considered and approved issuance of a Corporate Guarantee of Rs. 17,00,00,000 in favour of Citibank N.A. in respect of working capital facilities availed by Florida Pharmaceutical Products LLC, step down subsidiary of the Company. INDOCO REMEDIES LTD. - 532612 - Results For The Quarter And Half Year Ended 30Th September, 2023
Approval of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30th September, 2023 INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On 19Th October, 2023
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 19th October, 2023 has inter-alia considered and approved the following. 1. Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. 2. Issuance of a Corporate Guarantee of Rs. 17,00,00,000 in favour of Citibank N.A. in respect of the working capital facilities to be availed by Florida Pharmaceutical Products LLC, step down subsidiary of the Company.
Indoco Remedies Share Price Live blog for 18 Oct 2023
Indoco Remedies stock price went down today, 18 Oct 2023, by -0.47 %. The stock closed at 343.65 per share. The stock is currently trading at 342.05 per share. Investors should monitor Indoco Remedies stock price closely in the coming days and weeks to see how it reacts to the news. Indoco Remedies Share Price Live blog for 17 Oct 2023
Indoco Remedies stock price went down today, 17 Oct 2023, by -0.39 %. The stock closed at 343.65 per share. The stock is currently trading at 342.3 per share. Investors should monitor Indoco Remedies stock price closely in the coming days and weeks to see how it reacts to the news. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that an Earnings Conference Call on Unaudited Financial Results for the quarter and half year ended 30th September, 2023 is scheduled to be held on Thursday, 19th October, 2023 at 03:30 P.M. IST. INDOCO REMEDIES LTD. - 532612 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
ATTACHED CERTIFICATE ISSUED BY LINK INTIME INDIA PVT LTD, REGISTRAR & TRANSFER AGENT OF THE COMPANY, CONFIRMING COMPLIANCE UNDER REG 74(5) OF SEBI (D&P) REG,2018 FOR THE QTR ENDED 30-09-2023 INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2023 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30th September, 2023. the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30th September, 2023. INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2023 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30th September, 2023. INDOCO REMEDIES LTD. - 532612 - Closure of Trading Window
The trading window for trading/dealing in Equity shares of the Company will remain closed from 01st October, 2023 till 48 hours after declaration of standalone and consolidated financial results of the Company for the quarter and half year ended 30th September, 2023.